wm-s1-030

WM-S1-030 is a novel small molecule inhibitor developed by Wellmarker Bio targeting mutant receptor tyrosine kinases (mtRTKs). It functions as a protein tyrosine kinase inhibitor and is being investigated primarily for the treatment of advanced or metastatic solid tumors. Preclinical studies have demonstrated that WM-S1-030 can inhibit tumor growth in colorectal cancer models resistant to cetuximab (Erbitux), suggesting potential efficacy in patients with both KRAS wild-type and KRAS mutant genotypes. The drug has shown promising results in patient-derived cell and xenograft models across various cancers. Clinical development has focused on evaluating its safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy in patients with advanced solid tumors who have exhausted standard therapies[1][5][6][7].

Other names

WM-S1-030WM-S-1-030WM-S 1-030WM S1 030WM-S1-1030WM-S-1-1030WM-S 1-1030